ArticleSouth Asian journal of cancer2025
Immunohistochemical Subclassification of Peripheral T Cell Lymphomas-Not Otherwise Specified.
Article in South Asian journal of cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Peripheral T cell lymphomas-not otherwise specified (PTCL-NOS) are a heterogeneous group of mature T cell lymphomas that do not belong to any specified subtype. Gene expression profiling has revealed two biological variants of PTCL-NOS, PTCLGATA3 and PTCLTBX21. This study aims to subclassify PTCL-NOS using immunohistochemistry (IHC) and to establish its implication in prognosis. Methods: A descriptive study was done using 39 morphologically and immunohistochemically diagnosed cases of PTCL diagnosed over a 10-year period, 2013 to 2022. The additional IHC markers used were GATA3 and CCR4 for PTCLGATA3 and TBX21 and CXCR3 for PTCLTBX21. All cases had a minimum follow-up of 6 months. Results: After subclassification of PTCL-NOS ( Conclusion: Subcategorization of PTCL-NOS based on the IHC markers helps in the stratification of this disease. This will also identify cases with more aggressive behavior at the time of diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.